ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846
-A A +A

TRIPS and India's Pharmaceuticals Industry

Major changes can be expected in the Indian pharmaceuticals industry from 2005 due to the agreement on TRIPS, under which India will be required to introduce product patents for pharmaceutical products. This will likely lead to sharp increases in the prices of newly patented drugs. Although the TRIPS agreement may also lead to increased research on diseases common in developing countries, these benefits can be obtained in alternative ways, and without high costs. Thus, the TRIPS agreement is not in the national interest and should be renegotiated.



Subscribers please login to access full text of the article.

New 3 Month Subscription
to Digital Archives at

826for India

$50for overseas users

Get instant access to the complete EPW archives

Subscribe now

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top